Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells.
暂无分享,去创建一个
G. Kao | E. Harris | M. Dowling | G. Chan | M. K. Keutmann | Eric A. Lee
[1] M. Cammer,et al. Gene expression and mitotic exit induced by microtubule-stabilizing drugs. , 2003, Cancer research.
[2] Takashi Takahashi,et al. Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. , 2003, The American journal of pathology.
[3] Z. Bonday,et al. Centromere-associated protein-E is essential for the mammalian mitotic checkpoint to prevent aneuploidy due to single chromosome loss , 2003, The Journal of cell biology.
[4] Y. Mao,et al. Activating and Silencing the Mitotic Checkpoint through CENP-E-Dependent Activation/Inactivation of BubR1 , 2003, Cell.
[5] K. Sullivan,et al. Suppression of centromere dynamics by Taxol in living osteosarcoma cells. , 2003, Cancer research.
[6] T. Ried,et al. Inhibition of BUB1 results in genomic instability and anchorage-independent growth of normal human fibroblasts. , 2003, Cancer research.
[7] Stephen S. Taylor,et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores , 2003, The Journal of cell biology.
[8] M. Guenther,et al. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response , 2003, The Journal of cell biology.
[9] A. Riva,et al. Second generation taxanes: from the natural framework to the challenge of drug resistance. , 2003, Current medicinal chemistry. Anti-cancer agents.
[10] K. Sullivan,et al. Centromeres and Kinetochores From Epigenetics to Mitotic Checkpoint Signaling , 2003, Cell.
[11] A. Musacchio,et al. The spindle checkpoint: structural insights into dynamic signalling , 2002, Nature Reviews Molecular Cell Biology.
[12] Rey-Huei Chen,et al. BubR1 is essential for kinetochore localization of other spindle checkpoint proteins and its phosphorylation requires Mad1 , 2002, The Journal of cell biology.
[13] E. Gabrielson,et al. Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer. , 2002, The American journal of pathology.
[14] S. Kaufmann,et al. G1 and G2 cell-cycle arrest following microtubule depolymerization in human breast cancer cells , 2002 .
[15] E. Salmon,et al. Inducing precocious anaphase in cultured mammalian cells. , 2002, Cell motility and the cytoskeleton.
[16] Stephen S. Taylor,et al. Kinetochore localisation and phosphorylation of the mitotic checkpoint components Bub1 and BubR1 are differentially regulated by spindle events in human cells. , 2001, Journal of cell science.
[17] B. Hill,et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. , 2001, Molecular pharmacology.
[18] W. Mckenna,et al. Detection of repair activity during the DNA damage-induced G2 delay in human cancer cells , 2001, Oncogene.
[19] Carl W. Miller,et al. Mutations in the mitotic check point gene, MAD1L1, in human cancers , 2001, Oncogene.
[20] M. Kavallaris,et al. The role of β-tubulin isotypes in resistance to antimitotic drugs , 2001 .
[21] B. Sikic,et al. MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells , 2000, British Journal of Cancer.
[22] E. Nogales,et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[23] L. Milas,et al. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] T. Fojo,et al. Molecular effects of paclitaxel: Myths and reality (a critical review) , 1999, International journal of cancer.
[25] G. Chan,et al. Human Bubr1 Is a Mitotic Checkpoint Kinase That Monitors Cenp-E Functions at Kinetochores and Binds the Cyclosome/APC , 1999, The Journal of cell biology.
[26] L. Meijer,et al. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. , 1999, Journal of medicinal chemistry.
[27] P Wadsworth,et al. Taxol suppresses dynamics of individual microtubules in living human tumor cells. , 1999, Molecular biology of the cell.
[28] M. Polymeropoulos,et al. Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P‐glycoprotein, in drug‐selected cell lines and patients with drug refractory ALL , 1998, Genes, chromosomes & cancer.
[29] L. Milas,et al. Docetaxel enhances tumor radioresponse in vivo. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] M. Kavallaris,et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. , 1997, The Journal of clinical investigation.
[31] R. Muschel,et al. Cyclin B1 availability is a rate-limiting component of the radiation-induced G2 delay in HeLa cells. , 1997, Cancer research.
[32] C. Runowicz,et al. Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] R. Benjamin,et al. Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants , 1996, Cancer.
[34] J. Lynch,et al. A phase II trial of paclitaxel in the treatment of recurrent or metastatic soft tissue sarcomas or bone sarcomas. , 1996, Journal of experimental therapeutics & oncology.
[35] J. B. Rattner,et al. CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis , 1995, The Journal of cell biology.
[36] A. C. Dubbelman,et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] M. Jordan,et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[38] M. Jordan,et al. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. , 1992, Journal of cell science.
[39] M. Gottesman,et al. Isolation of a taxol-resistant Chinese hamster ovary cell mutant that has an alteration in alpha-tubulin. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[40] J. Lee,et al. Effects of nocodazole on structures of calf brain tubulin. , 1980, Biochemistry.
[41] P. Schiff,et al. Taxol stabilizes microtubules in mouse fibroblast cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[42] M. De Brabander,et al. Interaction of oncodazole (R 17934), a new antitumoral drug, with rat brain tubulin. , 1976, Biochemical and biophysical research communications.
[43] G. Chan,et al. The mitotic checkpoint: a signaling pathway that allows a single unattached kinetochore to inhibit mitotic exit. , 2003, Progress in cell cycle research.
[44] S. Kaufmann,et al. G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. , 2002, The Journal of clinical investigation.
[45] M. Shichiri,et al. Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. , 2002, Cancer research.
[46] Erich A. Nigg,et al. Cell division: Mitotic kinases as regulators of cell division and its checkpoints , 2001, Nature Reviews Molecular Cell Biology.
[47] B. Pollock. Obstacles and opportunities for the use of health‐related quality‐of‐life assessment in pediatric cancer clinical trials (discussion) , 1999, International journal of cancer. Supplement = Journal international du cancer. Supplement.